Skip to main content
. 2023 Feb 6;12(4):529. doi: 10.3390/cells12040529

Figure 3.

Figure 3

Generation of synthetic fetal liver organoids using human iPSCs can provide a novel platform for human liver repopulation during diseased conditions. Human skin cells can be reprogrammed to human iPSCs using reprogramming factors. Developed iPSCs can differentiate toward synthetic multicellular fetal liver organoids using, e.g., GATA6 genetic circuits. Produced organoids can represent a human cell source with a potentially competitive advantage for therapeutic liver repopulation.